Revenue rose 22%
Group quarterly revenue changed from 245 ₹ crore (Q2 FY26) to 299 ₹ crore (Q2 FY27). Revenue rose 22%.
Watch: Disaggregate subsidiary sales
Home / Research / Clean Science and Technology Limited
Revenue rose 22%
Group quarterly revenue changed from 245 ₹ crore (Q2 FY26) to 299 ₹ crore (Q2 FY27). Revenue rose 22%.
Watch: Disaggregate subsidiary sales
Group quarterly EBITDA changed from 87 ₹ crore (Q2 FY26) to 92 ₹ crore (Q2 FY27). EBITDA rose only 5%.
Watch: Test incremental profit
Group EBITDA margin changed from 36.4 % (Q2 FY26) to 31.2 % (Q2 FY27). Margin contracted 520bps.
Watch: Watch materials and yield
Group PAT changed from 55 ₹ crore (Q2 FY26) to 56 ₹ crore (Q2 FY27). PAT barely improved.
Watch: Reconcile cash
Quarter ended 30 September 2026 · Stance WATCH · original issuer/exchange sources. The investor question is whether newly commercializing HALS chemistry can restore growth without permanently diluting an established specialty-chemical margin structure. Consolidated revenue grew from ₹245 crore to ₹299 crore, but EBITDA improved only from ₹87 crore to ₹92 crore. At 31.2% group EBITDA margin versus 36.4% a year earlier, stronger top line does not yet prove attractive incremental returns. WATCH until new capacity generates reliable cash and a sustainable product-margin mix. [S1][S2]
| Decision metric | Earlier reference | Latest reference |
|---|---|---|
| Group quarterly revenue | 245 ₹ crore (Q2 FY26) | 299 ₹ crore (Q2 FY27) |
| Group quarterly EBITDA | 87 ₹ crore (Q2 FY26) | 92 ₹ crore (Q2 FY27) |
| Group EBITDA margin | 36.4 % (Q2 FY26) | 31.2 % (Q2 FY27) |
| Group PAT | 55 ₹ crore (Q2 FY26) | 56 ₹ crore (Q2 FY27) |
| Standalone quarterly sales | 211 ₹ crore (Q2 FY26) | 233 ₹ crore (Q2 FY27) |
| Standalone EBITDA | 90 ₹ crore (Q2 FY26) | 82 ₹ crore (Q2 FY27) |
| Consolidated H1 revenue | 488 ₹ crore (H1 FY26) | 568 ₹ crore (H1 FY27) |
| Consolidated H1 EBITDA | 187 ₹ crore (H1 FY26) | 188 ₹ crore (H1 FY27) |
Key takeaways: Group quarterly revenue: Revenue rose 22%. Group quarterly EBITDA: EBITDA rose only 5%. Group EBITDA margin: Margin contracted 520bps. Group PAT: PAT barely improved. Standalone quarterly sales: Core sales improved. Standalone EBITDA: Mature site EBITDA weakened. All comparisons follow the issuer's specified dates, basis and units. The separate graphical Investment Briefing precedes the detailed main report.
The investor question is whether newly commercializing HALS chemistry can restore growth without permanently diluting an established specialty-chemical margin structure. Consolidated revenue grew from ₹245 crore to ₹299 crore, but EBITDA improved only from ₹87 crore to ₹92 crore. At 31.2% group EBITDA margin versus 36.4% a year earlier, stronger top line does not yet prove attractive incremental returns. WATCH until new capacity generates reliable cash and a sustainable product-margin mix. [S1][S2]
Issuer-specific financial checks and decisions
Monitoring interpretation. Revenue rose 22%. The practical next-quarter test is: disaggregate subsidiary sales. EBITDA rose only 5%. The practical next-quarter test is: test incremental profit. Margin contracted 520bps. The practical next-quarter test is: watch materials and yield. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.
The Q2 standalone business reported ₹233 crore revenue versus ₹211 crore a year ago, but EBITDA declined from ₹90 crore to ₹82 crore; the subsidiary's contribution improves consolidated sales but cannot disguise core cost pressure. H1 consolidated revenue was ₹568 crore versus ₹488 crore, while EBITDA was nearly unchanged at ₹188 crore versus ₹187 crore. Product/raw-material costs increased substantially. Distinguish reported group PAT of approximately ₹56 crore from underlying EBITDA and operating-cash-flow conversion. [S1][S2]
Issuer-specific financial checks and decisions
Monitoring interpretation. Margin contracted 520bps. The practical next-quarter test is: watch materials and yield. PAT barely improved. The practical next-quarter test is: reconcile cash. Core sales improved. The practical next-quarter test is: review export realization. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.
The core performance, pharmaceutical and FMCG intermediates are established products, whereas HALS output through Clean Fino Chem is still scaling. Management reported HALS approximately doubled in revenue on a year-over-year basis and reached roughly 22% of sales. The top four legacy products account for about 58% now versus about 85% in Q4 FY23. That diversifies sales sources but adds qualification and process-yield risks; sales share is not necessarily profit share. [S1][S2]
Issuer-specific financial checks and decisions
Monitoring interpretation. Core sales improved. The practical next-quarter test is: review export realization. Mature site EBITDA weakened. The practical next-quarter test is: watch input costs. Six-month growth about 16%. The practical next-quarter test is: review utilization. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.
CFCL was described as adding roughly ₹48 crore of year-on-year sales and attaining positive PAT. The presentation said advanced HALS products underwent customer qualification with Geneus Chem AG, and additional performance chemicals were expected to commercialize in H2 FY27. These are milestones with verification dependencies rather than reported future revenue. Investors need approved customer grades, repeat volumes and yield data to distinguish product adoption from early orders. [S1][S2]
Issuer-specific financial checks and decisions
Monitoring interpretation. Six-month growth about 16%. The practical next-quarter test is: review utilization. Six-month EBITDA flat. The practical next-quarter test is: test ramp economics. PAT rose about 3%. The practical next-quarter test is: check cost normalization. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.
The company invested approximately ₹150 crore during H1 FY27 in CFCL. Consolidated inventories increased to ₹221 crore from ₹154 crore at March 2026, and receivables to ₹263 crore from ₹206 crore. These movements can absorb cash during a manufacturing ramp despite EBITDA profitability. The corporate presentation calls the firm zero debt; no fabricated period-specific free cash flow is derived without a reconciled cash-flow statement. [S1][S2]
Issuer-specific financial checks and decisions
Monitoring interpretation. PAT rose about 3%. The practical next-quarter test is: check cost normalization. Raw materials grew by one third. The practical next-quarter test is: monitor input contracts. Inventory tied up more capital. The practical next-quarter test is: track turnover. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.
Bull: higher HALS utilization, product qualifications and normalized input costs restore margin from 31.2%. Base: revenue grows but subsidiary startup, process yields and raw material costs absorb much of the incremental profit. Bear: delayed acceptance, prolonged commodity inflation or rising inventory/receivables impair cash returns. Each scenario is falsifiable through customer repeat ordering, gross margin, and working-capital metrics rather than unsupported share-price targets. [S1][S2]
Issuer-specific financial checks and decisions
Monitoring interpretation. Revenue rose 22%. The practical next-quarter test is: disaggregate subsidiary sales. EBITDA rose only 5%. The practical next-quarter test is: test incremental profit. Margin contracted 520bps. The practical next-quarter test is: watch materials and yield. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.
WATCH and track core/CFCL margins separately. Observe standalone EBITDA ₹82 crore, group EBITDA ₹92 crore, the 22% HALS sales share, approximate H1 capex ₹150 crore, inventories ₹221 crore and receivables ₹263 crore. Reconcile growth from new products against their utilization, customer reorders and collected revenue. Demand at least two quarters of better conversion before capitalizing the next HALS grade launch at a premium valuation. [S1][S2]
Issuer-specific financial checks and decisions
Monitoring interpretation. Margin contracted 520bps. The practical next-quarter test is: watch materials and yield. PAT barely improved. The practical next-quarter test is: reconcile cash. Core sales improved. The practical next-quarter test is: review export realization. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.
[S1] — management discussion and analyst questions for the September 2026 quarter. [S2] — issuer financial and operating data.
Interpretive limits: Future product launches, order contracts, customer discussions, raw-material effects and project milestones are cited as management commentary where relevant, not realized future profits. Valuation figures, project payback, market prices, leverage and cash conversions are omitted where the saved issuer evidence is inadequate.
Original references are in the published manuscript below.
This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.